Logo image of TIL

INSTIL BIO INC (TIL) Stock Price, Quote, News and Overview

NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD

13.17  -0.51 (-3.73%)

TIL Quote, Performance and Key Statistics

INSTIL BIO INC

NASDAQ:TIL (5/13/2025, 2:42:01 PM)

13.17

-0.51 (-3.73%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High92
52 Week Low9.62
Market Cap86.40M
Shares6.56M
Float6.02M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11/bmo
IPO03-19 2021-03-19


TIL short term performance overview.The bars show the price performance of TIL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

TIL long term performance overview.The bars show the price performance of TIL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of TIL is 13.17 USD. In the past month the price decreased by -8.98%. In the past year, price increased by 18.96%.

INSTIL BIO INC / TIL Daily stock chart

TIL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.39 334.14B
AMGN AMGEN INC 13.08 146.05B
GILD GILEAD SCIENCES INC 13.2 127.15B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.50B
REGN REGENERON PHARMACEUTICALS 12.87 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.51B
ARGX ARGENX SE - ADR 91.99 32.97B
ONC BEIGENE LTD-ADR 5.54 24.04B
BNTX BIONTECH SE-ADR N/A 22.89B
NTRA NATERA INC N/A 20.73B
SMMT SUMMIT THERAPEUTICS INC N/A 18.40B
BIIB BIOGEN INC 7.82 18.12B

About TIL

Company Profile

TIL logo image Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

Company Info

INSTIL BIO INC

3963 Maple Avenue, Suite 350

Dallas TEXAS 75219 US

CEO: Bronson Crouch

Employees: 49

TIL Company Website

TIL Investor Relations

Phone: 19724993350

INSTIL BIO INC / TIL FAQ

What is the stock price of INSTIL BIO INC today?

The current stock price of TIL is 13.17 USD. The price decreased by -3.73% in the last trading session.


What is the ticker symbol for INSTIL BIO INC stock?

The exchange symbol of INSTIL BIO INC is TIL and it is listed on the Nasdaq exchange.


On which exchange is TIL stock listed?

TIL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INSTIL BIO INC stock?

8 analysts have analysed TIL and the average price target is 115.94 USD. This implies a price increase of 780.33% is expected in the next year compared to the current price of 13.17. Check the INSTIL BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INSTIL BIO INC worth?

INSTIL BIO INC (TIL) has a market capitalization of 86.40M USD. This makes TIL a Micro Cap stock.


How many employees does INSTIL BIO INC have?

INSTIL BIO INC (TIL) currently has 49 employees.


What are the support and resistance levels for INSTIL BIO INC (TIL) stock?

INSTIL BIO INC (TIL) has a support level at 13.07 and a resistance level at 14.49. Check the full technical report for a detailed analysis of TIL support and resistance levels.


Should I buy INSTIL BIO INC (TIL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INSTIL BIO INC (TIL) stock pay dividends?

TIL does not pay a dividend.


When does INSTIL BIO INC (TIL) report earnings?

INSTIL BIO INC (TIL) will report earnings on 2025-08-11, before the market open.


What is the Price/Earnings (PE) ratio of INSTIL BIO INC (TIL)?

INSTIL BIO INC (TIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.39).


What is the Short Interest ratio of INSTIL BIO INC (TIL) stock?

The outstanding short interest for INSTIL BIO INC (TIL) is 9.33% of its float. Check the ownership tab for more information on the TIL short interest.


TIL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TIL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TIL. TIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TIL Financial Highlights

Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.39. The EPS increased by 52.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.13%
ROE -43.75%
Debt/Equity 0.5
Chartmill High Growth Momentum
EPS Q2Q%8.54%
Sales Q2Q%N/A
EPS 1Y (TTM)52.52%
Revenue 1Y (TTM)N/A

TIL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to TIL. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners78.56%
Ins Owners10.98%
Short Float %9.33%
Short Ratio4.56
Analysts
Analysts82.5
Price Target115.94 (780.33%)
EPS Next Y0.46%
Revenue Next YearN/A